Molecular Mechanisms of Cancer Program, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Salamanca, 37007, Salamanca, Spain.
Instituto de Investigación Biomédica de Salamanca (IBSAL), Hospital Universitario de Salamanca, 37007, Salamanca, Spain.
J Mol Med (Berl). 2024 Jun;102(6):801-817. doi: 10.1007/s00109-024-02442-8. Epub 2024 Mar 30.
Rare recessive variants in the human VRK1 gene are associated with several motor neuron diseases (MND), such as amyotrophic lateral sclerosis, spinal muscular atrophy, or distal hereditary motor neuropathies (dHMN). A case with dHMN carrying two novel VRK1 gene variants, expressing Leu200Pro (L200P) and Arg387His (R387H) variant proteins, identified that these protein variants are functionally different. The Leu200Pro variant shares with several variants in the catalytic domain the loss of the kinase activity on different substrates, such as histones, p53, or coilin. However, the distal Arg387His variant and the distal Trp375* (W375X) chinese variant, both located at the end of the low complexity C-terminal region and proximal to the termination codon, retain their catalytic activity on some substrates, and mechanistically their functional impairment is different. The L200P variant, as well as most VRK1 pathogenic variants, impairs the phosphorylation of BAF and histone H4K16 acetylation, which are required for DNA attachment to the nuclear envelope and chromatin accessibility to DNA repair mechanisms, respectively. The R387H variant impairs phosphorylation of H2AX, an early step in different types of DNA damage responses. The functional variability of VRK1 protein variants and their different combinations are a likely contributor to the clinical phenotypic heterogeneity of motor neuron and neurological diseases associated with rare VRK1 pathogenic variants. KEY MESSAGES: VRK1 variants implicated in motor neuron diseases are functionally different. The L200P variant is kinase inactive, and the R387H variant is partially active. VRK1 variants alter H4K16 acetylation and loss of coilin and BAF phosphorylation. VRK1 variants alter Cajal bodies and DNA damage responses. VRK1 variant combination determines the neurological phenotype heterogeneity.
人类 VRK1 基因中的罕见隐性变异与多种运动神经元疾病(MND)相关,例如肌萎缩侧索硬化症、脊髓性肌萎缩症或远端遗传性运动神经病(dHMN)。一例携带两个新 VRK1 基因突变的 dHMN 病例,表达亮氨酸 200 脯氨酸(L200P)和精氨酸 387 组氨酸(R387H)变异蛋白,鉴定出这些蛋白变异在功能上有所不同。亮氨酸 200 脯氨酸变异与催化结构域中的几个变异共享,导致对不同底物(如组蛋白、p53 或 coilin)的激酶活性丧失。然而,位于低复杂度 C 端末端和终止密码子附近的远端精氨酸 387 组氨酸变异和远端色氨酸 375*(W375X)中国变异保留了它们对一些底物的催化活性,并且在机制上它们的功能障碍不同。L200P 变异以及大多数 VRK1 致病性变异会损害 BAF 和组蛋白 H4K16 乙酰化的磷酸化,这分别是 DNA 附着到核膜和染色质可及性以进行 DNA 修复机制所必需的。R387H 变异会损害 H2AX 的磷酸化,H2AX 是各种 DNA 损伤反应的早期步骤。VRK1 蛋白变异的功能可变性及其不同组合可能是导致与罕见 VRK1 致病性变异相关的运动神经元和神经疾病临床表型异质性的原因之一。
与运动神经元疾病相关的 VRK1 变异在功能上有所不同。
L200P 变体是无激酶活性的,而 R387H 变体是部分活性的。
VRK1 变体改变 H4K16 乙酰化以及 coilin 和 BAF 磷酸化的丧失。
VRK1 变体改变 Cajal 体和 DNA 损伤反应。
VRK1 变体组合决定神经表型的异质性。